Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety
about
The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trialsClinical Translation of Nanomedicine.Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Nanoparticle-based drug delivery to the vagina: a review.Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection.Efficacy of HIV antiviral polyanionic carbosilane dendrimer G2-S16 in the presence of semenMicrobicides: still a long road to successDendrimers for gene delivery--a potential approach for ocular therapy?Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.Preclinical studies of dendrimer prodrugs.Nanomaterials in the Context of Type 2 Immune Responses-Fears and Potentials.The role of nanotechnology in the treatment of viral infections.G2-S16 dendrimer as a candidate for a microbicide to prevent HIV-1 infection in women.Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides.Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
P2860
Q28087336-B05FC27C-2758-4EBA-B940-5E7E9D60DAB0Q30355939-AE16EB44-9C6A-4B01-9691-C2F8FD055BDEQ30412592-49A7F2D1-FE5B-439A-BAFB-C7ACA8624896Q30431343-B921A201-7F53-47F9-A14F-6FC831261667Q33821090-573E2A61-9B88-4E96-9B1A-A482C7BC7A8FQ34079533-7CD49159-69B2-45ED-A9AC-3329BD22F100Q35905458-9C896AD1-6D45-40E3-92C1-1E094B84DCEEQ36967950-C8689868-B6D8-490B-B74B-8D55891D3ECAQ37130757-B302A71D-2EEE-4743-A6BA-453BF9DE69AFQ38196447-7443CABC-0E3D-4AF2-A326-B683FD5F17C3Q38260862-8F214193-1552-4740-BF14-82EB8B819861Q38509638-453CD17A-8762-4611-816B-757324E26DFFQ39294509-3B050866-7D5A-4794-BD37-7AC0B69A898CQ40106774-0B231D17-66A4-404C-BB3B-DDE2AC63E73FQ40135804-7F1E8671-A5F5-46C2-8595-4EEB73EF6C1AQ41051936-ABF29D87-03E7-4F36-AF38-49AB6AB8B956Q41339468-B4BEF86F-FF77-4F38-9589-071934EE97D6
P2860
Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Measurement of mucosal biomark ...... Gel) to assess expanded safety
@ast
Measurement of mucosal biomark ...... Gel) to assess expanded safety
@en
type
label
Measurement of mucosal biomark ...... Gel) to assess expanded safety
@ast
Measurement of mucosal biomark ...... Gel) to assess expanded safety
@en
prefLabel
Measurement of mucosal biomark ...... Gel) to assess expanded safety
@ast
Measurement of mucosal biomark ...... Gel) to assess expanded safety
@en
P2093
P2860
P50
P1476
Measurement of mucosal biomark ...... Gel) to assess expanded safety
@en
P2093
Anna-Barbara Moscicki
Anuradha Rebbapragada
Ibrahim I Daud
Mark E Scott
Sanja Huibner
Stephen Shiboski
P2860
P304
P356
10.1097/QAI.0B013E31823F2AEB
P407
P577
2012-02-01T00:00:00Z